Tegavivint suppresses chemotherapy-resistant and metastatic osteosarcoma by disturbing β-catenin-TBL1 binding8, and SUMOylation of TBL1/TBLR1 promotes the migration and invasion of bladder cancer cells9. The gene discussed is TBL1X; the disease is urinary bladder cancer.